3 active not recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow IPI-145: new trials by email Literature Review of IPI-145 trials Research Report on IPI-145
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome Biospecimen Collection, Computed Tomography, Duvelisib - Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 38 | 2021-10-21 | 2026-07-31 |
| Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Duvelisib, Venetoclax - Chronic Lymphocytic Leukemia, Richter Syndrome | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 55 | 2018-07-12 | 2026-03-23 |
| A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL IPI-145, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 32 | 2014-06-27 | 2026-10-22 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Mycosis Fungoides (1) · Sezary Syndrome (1)
Dana-Farber Cancer Institute (2) · National Cancer Institute (NCI) (1)
United States (3)
Matthew Davids, MD (1) · Matthew S Davids, MD (1) · Neha Mehta-Shah (1)
UM1CA186689 (1)